Share-based Payment Arrangement, Expense of Ernexa Therapeutics Inc. from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ernexa Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • Ernexa Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $293,000, a 28% decline year-over-year.
  • Ernexa Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,573,000, a 23% increase year-over-year.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,520,000, a 22% increase from 2023.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,242,000, a 58% decline from 2022.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,935,000, a 44% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Ernexa Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,573,000 $293,000 -$112,000 -28% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $1,685,000 $368,000 -$55,000 -13% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $1,740,000 $502,000 +$220,000 +78% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $1,520,000 $410,000 +$245,000 +148% 01 Oct 2024 31 Dec 2024 10-K 12 Mar 2025 2024 FY
Q3 2024 $1,275,000 $405,000 +$231,000 +133% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 $1,044,000 $423,000 +$209,000 +98% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $835,000 $282,000 -$407,000 -59% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $1,242,000 $165,000 -$232,000 -58% 01 Oct 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
Q3 2023 $1,474,000 $174,000 -$302,000 -63% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $1,776,000 $214,000 -$665,000 -76% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $2,441,000 $689,000 -$494,000 -42% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $2,935,000 $397,000 -$1,786,004 -82% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $4,721,004 $476,000 -$1,253,000 -72% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $5,974,004 $879,000 -$275,000 -24% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $6,249,004 $1,183,000 +$1,014,004 +600% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $5,235,000 $2,183,004 +$2,160,206 +9475% 01 Oct 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
Q3 2021 $3,074,794 $1,729,000 +$1,706,266 +7505% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $1,368,528 $1,154,000 +$1,131,266 +4976% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $237,262 $168,996 +$146,262 +643% 01 Jan 2021 31 Mar 2021 10-Q 17 May 2021 2021 Q1
Q4 2020 $91,000 $22,798 01 Oct 2020 31 Dec 2020 10-K/A 01 Jul 2022 2021 FY
Q3 2020 $22,734 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $22,734 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 $22,734 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q1 2015 $99,000 +$47,000 +90% 01 Jan 2015 31 Mar 2015 10-Q 08 May 2015 2015 Q1
Q1 2014 $52,000 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q1

Ernexa Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,520,000 +$278,000 +22% 01 Jan 2024 31 Dec 2024 10-K 12 Mar 2025 2024 FY
2023 $1,242,000 -$1,693,000 -58% 01 Jan 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
2022 $2,935,000 -$2,300,000 -44% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $5,235,000 +$5,144,000 +5653% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
2020 $91,000 01 Jan 2020 31 Dec 2020 10-K/A 01 Jul 2022 2021 FY
2013 $132,000 -$53,000 -29% 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2014 2013 FY
2012 $185,000 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.